Status:

RECRUITING

STICH3C Cardiac Magnetic Resonance Observational Study

Lead Sponsor:

Weill Medical College of Cornell University

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Ischemic Left Ventricle Systolic Dysfunction

Multivessel Coronary Artery Disease

Eligibility:

All Genders

18+ years

Brief Summary

STICOS will test the hypothesis that residual jeopardized myocardium, late gadolinium enhancement, and non-ischemic substrate after revascularization is associated with postoperative adverse cardiovas...

Detailed Description

iLVSD (ischemic left ventricular dysfunction) is a leading cause of heart failure (HF) and death. It is widely treated via coronary revascularization despite limited understanding of determinants of r...

Eligibility Criteria

Inclusion

  • Men and women ≥ 18 years old
  • LVEF ≤ 40% (quantified by echo, single-photon emission computed tomography \[SPECT\], or CMR within 2 months of enrollment)
  • Prognostically important CAD: either multivessel CAD (triple vessel or double vessel CAD including left anterior descendant artery (LAD), significant coronary stenosis defined as ≥ 70% based on coronary angiography, fractional flow reserve (FFR) ≤ 0.80 or instantaneous wave-free ratio (iFR) ≤ 0.89) or left main disease (+/- other CAD) for which significant stenosis defined as \> 50% based on coronary angiography, intravascular ultrasound (IVUS) minimum luminal area \[MLA\] value ≤ 6.0 mm2 (\< 4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements.
  • Planned CABG or PCI within 3 months

Exclusion

  • Concomitant valve disease or other condition (e.g., LV aneurysm) requiring surgical repair or replacement
  • Contraindication to CMR (i.e. magnetically activated materials), gadolinium, regadenoson/adenosine/dipyridamole
  • Active neoplasm and/or severe end-organ dysfunction with expected life expectancy less than 5 years.
  • \-

Key Trial Info

Start Date :

March 1 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 1 2030

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT07133984

Start Date

March 1 2024

End Date

January 1 2030

Last Update

August 21 2025

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

NewYork-Presbyterian Brooklyn Methodist Hospital

Brooklyn, New York, United States, 11215

2

New York Presbyterian - Queens

Flushing, New York, United States, 11355

3

Weill Cornell Medicine/NewYork Presbyterian Hospital

New York, New York, United States, 10022

4

MU Vienna Austria

Vienna, Austria